Background.Travellers' diarrhoea (TD) is a common problem, affecting millions of tourists each year and creating a large economic burden. Risk factors for TD are known and guidelines exist to assist practitioners in advising travellers on how to prevent and treat TD. However, data are lacking regarding actual prescribing practices or approaches used in TD management. This study aims to establish a baseline which identifies uniformities and diversities in practice.
Background
Travellers' diarrhoea (TD) is a common problem, affecting millions of tourists each year, 1 and creating a large economic burden. 2 Risk factors for TD are known [3] [4] [5] and efforts have been made to develop evidence-based guidelines 6, 7 to assist travellers in preventing and self-treating TD. Recent emerging evidence has demonstrated that the use of antibiotics for TD while abroad, as well as the development of TD itself, are associated with increased risk of gastrointestinal colonization with highly resistant organisms. [8] [9] [10] [11] [12] [13] This has heightened the importance of ensuring that the advice given by travel practitioners regarding self-treatment of TD is consistent, targeted and evidence-based. Improvement in the management of TD has the potential to result in reduced morbidity, 14, 15 reduced costs and reduced colonization, ultimately limiting the subsequent introduction of resistant organisms into the community and healthcare facilities following return home.
What is currently missing from the literature is any exploration of actual prescribing practices or approaches used in TD management amongst clinicians who regularly see travellers for pre-travel consultations. It is not known whether the topic is always comprehensively discussed, what specific aspects of advice are given, or how consistent practices are across the profession. This study aims to establish a baseline of practice according to case-based scenarios and to identify diversities in approaches.
Methods
An online survey created using the SurveyMonkey tool was developed to test respondent approaches to TD pre-travel management according to four different clinical scenarios. Respondents were able to select options from multiple choice answers or enter free text for most questions. A small number of general questions about the management of TD in the pre-travel context were also included. In all, there were 42 questions including demographic questions such as age, country of practice and clinical speciality. An invitation to participate in the survey was distributed with permission through selected Australian and New Zealand speciality travel medicine centres as well as through the electronic mailing list of the 
Results

Demographics
Three hundred and sixty-four fully completed (78%) or partially completed surveys were collected, with demographic questions towards the end of the survey the most likely to be missing. Responses were from 23 different countries (Table 1) , with the majority of respondents from the United States of America (26%), Australia (17%), New Zealand (16%), Canada (11%) or Europe (6%). The majority of respondents were doctors in primary care (36%), followed by nurses (13%) then infectious diseases physicians (8%), and over a third (37%) had practiced travel medicine for 10 or more years. About 71% of respondents stated they were aware of recent literature that associated antibiotic use for TD with an increased risk of colonization by resistant organisms, 12 53% of whom stated that this had changed their practice.
Approach to Travellers' Diarrhoea
The majority of respondents (71%) said they discussed TD with all patients as part of the travel medicine consult. However, when presented with the scenario of travel to New York and Boston by a healthy individual, only 32% indicated they would discuss TD (mainly preventative techniques) compared with 98% when travel was to Thailand and Cambodia. 53% of respondents practiced in centres with a policy for prescribing medications for TD and 87% provided written information of some kind to all travellers ( Table 2) .
The approach to specific travel scenarios are shown in Figure 1 . In the scenario where a healthy adult traveller was travelling to Thailand and Cambodia for a 2 month period, 85 and 72% would prescribe self-treatment with antibiotics and loperamide, respectively. In healthy children, respondents were less likely to prescribe self-treatment antibiotics (62%) and much less likely to prescribe loperamide (16%).
In healthy adults travelling to South East Asia, 38% of respondents said they would discuss the cholera vaccine while 23% would recommend a non-antibiotic preventative such as bismuth or a probiotic, and 4% would prescribe prophylactic antibiotics. In the 'at-risk' host (immunocompromised with a history of inflammatory bowel disease) on an important 3-day trip to India, this increased to 23% while 14% would recommend against travel. Hepatitis A vaccination and provision of an antiemetic were also considered important.
Antibiotic Choice
As shown in Table 3 , fluoroquinolones remain a popular choice for self-treatment in healthy travellers to Central America (68% overall), although less so for Australian prescribers (58% vs all others at 75%, P ¼ 0.03) who were more likely to prescribe azithromycin (57%). This regional variation in prescribing was not seen in all destinations; for travel to Vietnam all groups preferred non-fluoroquinolones. This was likely related to perceptions around pathogen resistance profiles given that 72% of respondents indicated that local resistance patterns were the most important consideration in choice; the side effect profile (25%) and ease of use (26%) were also considered significant factors. In the at-risk host travelling to India, those prescribing antibiotics for prophylaxis or self-treatment preferred azithromycin (35 and 65%, respectively), and 48% considered the high risk of consequences of TD to the traveller as the most important consideration. The local resistance pattern in India was the most influential factor (62%) in the choice of antibiotic for selftreatment; potential drug interactions also became more significant (45%) in at-risk groups, and discussing drug choices with the traveller's primary physician was important to many. For healthy children, azithromycin was the most popular antibiotic choice (70%) with local resistance patterns (51%), the side effect profile (51%) and ease of use (37%) again of importance.
Clinical Scenarios
Respondents were asked to select from a number of different clinical approaches in response to worsening symptoms in three different hypothetical patients-a healthy young traveller, an at risk host (an immunosuppressed recent liver transplant recipient with inflammatory bowel disease) and a 4-year-old child ( Figure 2 ). Illness severity was grouped according to categories as defined in De la Cabada Bauche and DuPont. 6 Most respondents felt in addition to hydration 'a wait and see' approach or 'a dose of loperamide' were the most suitable options for patients with mild illness (one loose bowel motion with no other systemic symptoms), although North Americans were more likely to advocate earlier loperamide use compared with Australians and New Zealanders in the healthy (23% vs 13%, P ¼ 0.038) and at risk (25% vs 10%, P ¼ 0.002) groups. Europeans were more likely to advocate for early medical review in the at-risk than their North American or Australasian counterparts (17% vs 5%, P ¼ 0.04). Loperamide was an unpopular choice in the child scenario (4%).
For otherwise healthy patients with moderate illness (less than 5 loose stools but disruptive without fevers or bloody diarrhoea) the favoured approach was loperamide alone (52%) (Figure 3 ). In the at-risk host, treatment tended to be more aggressive with 46% of respondents advocating a course of antibiotics, particularly among medical respondents (62% vs 46% non-medical, P ¼ 0.011), with 12% of respondents suggesting a need to seek medical attention. In children, greater conservatism in treatment was shown by medical respondents, with 47% preferring to wait and see compared with 21% of non-medical respondents (P < 0.001).
In severe illness (greater than 10 bloody stools) in the healthy individual, most respondents favoured antibiotics, with popular options evenly split between a full course and a single dose (26% each). 32% of respondents favoured antibiotic regimes plus loperamide and 13% advocated loperamide alone, while 15% preferred antibiotics alone. Travel practitioners with > 5 years' experience were more comfortable than those with less experience recommending only a single dose of antibiotics with re-evaluation based on symptoms (25% vs 4%, P < 0.001).
In severe illness with fever in the otherwise healthy, 59% of respondents favoured seeking medical attention (non-medical respondents more so than medical, 68% vs 54%, P ¼ 0.018) and 20% advocated taking a course of antibiotics alone ( Figure 4) . The presence of fever in severe illness saw less respondents recommend the use of loperamide, with only 10% recommending an antibiotic regime with loperamide and none suggesting loperamide alone. Australian respondents were less likely to suggest medical review (41%) than their New Zealand counterparts (70%, P ¼ 0.001) and accordingly more likely to recommend a course of antibiotics (53% vs 28%, P ¼ 0.007). Less experienced practitioners (<5 years' experience) were more likely to recommend seeking medical attention than the more experienced (69% vs 52% for >10 years, P ¼ 0.019), although in at-risk patients 73% recommended medical attention. 69% of respondents advocated seeking medical attention for a child with severe TD while 11% recommended a full course of antibiotics, although this varied by region of practice.
Discussion
Advice regarding management of TD is a core part of the pretravel consultation, with variability existing in recommendations according to individual practitioner preferences, country of destination, age and underlying health of the traveller, and symptom severity. Our results also suggest additional variability according to the respondents' professional background, region of practice and level of experience. Mild TD illness was generally treated with 'wait and see' or 'a dose of loperamide' across all traveller scenarios, which is in agreement with treatment guidelines as defined by De la Cabada Bauche and DuPont. 6 In moderate illness in the healthy individual, these clinical guidelines would advocate use of single dose antibiotics (with or without loperamide) with ongoing re-evaluation of the need for further doses. This approach was favoured amongst only 25% of respondents with most preferring the less aggressive option of treatment with loperamide alone (52%) or wait and see (10%). Europeans respondents were the least likely to prescribe any course of antibiotics (17%) in this scenario. Appropriately, a more aggressive approach was favoured in the at-risk patient group with more respondents recommending the use of antibiotics (46%). In severe illness, treatment with antibiotics is generally recommended, 6 as was favoured by the majority of respondents (77%). The addition of fever saw a higher proportion (59%) not inappropriately recommend medical review, and this increased further to 72% in the at-risk host. The responses to the clinical scenarios suggest most uniformity in recommended treatment strategies in clearly mild or severe disease, and greater variability in moderate disease. The evidence for benefits of antimicrobials in moderate and severe TD is strong [16] [17] [18] [19] with studies demonstrating more rapid cure of TD, on average within 24 h 20 and a hastened return to function.
Respondent use of loperamide with antibiotics differed according to disease severity, likely relating to perceptions around the safety of loperamide in severe diarrhoea or in the presence of fever. In the healthy and at-risk scenarios, practitioners were more likely to prescribe antibiotic regimes with loperamide in moderate disease compared with severe disease with fever (16% vs 10%, P < 0.013 in healthy; 24% vs 7%, P < 0.001 in at-risk).
However, when comparing the healthy traveller with moderate disease to severe disease without fever there was no significant difference in the number of practitioners who would recommend an antibiotic regime with or without loperamide (P ¼ 0.184), although far more were willing to recommend loperamide alone in moderate disease (52% vs 13% in severe disease without fever, P < 0.001). The presence of fever in severe illness saw less respondents recommend the use of loperamide containing regimes with or without antibiotics (10% vs 45% without fever, P < 0.001). While the majority of studies suggest that loperamide when combined with antibiotics leads to a more rapid improvement of symptoms [20] [21] [22] [23] [24] without any increase in adverse outcomes, many past studies have excluded severe bloody diarrhoea or fever because of concerns around the use on antimotility agents with invasive organisms. While a beneficial effect of combination therapy has not always been demonstrated, 25 no studies have shown any safety concerns in the TD population. However some guidelines 7, 26, 27 remain hesitant to recommend use of loperamide in diarrhoea with bloody stools or fevers, despite much of this concern being based on older evidence related to drugs with more potent antimotility actions or without concomitant antibiotics, 28 or not directly applicable to the TD population. 29 A recent systematic review found no significant evidence that loperamide is unsafe in the TD population and proposed this may be because most of the clinical benefit of loperamide is derived from its antisecretory effects rather than its antimotility actions. 30 Given the lack of data directly comparing loperamide alone versus antibiotics in the treatment of mild to moderate TD and the relative safety of loperamide compared with the known and increasing problems of antibiotics, this review also suggested that loperamide alone may be the treatment of choice in mild and moderate TD. Lower overall prescribing rates of loperamide in children meant there was no significant difference in the rates of prescribing loperamide in combination with antibiotics between moderate and severe illness, however there was regional variation in its use. In moderate disease, Europeans (50%), Australians (53%) and New Zealanders (44%) all preferred a wait and see approach when compared with respondents from the US (26%) or Canada (28%), who generally were more likely to consider antibiotics and/or loperamide instead (59% collectively). This possibly reflects different licensing regimes internationally for the use of loperamide in children: in Australia, it is not licenced for use in children less than 12 and in the United Healthy 32 year old male traveling through Mexico for three weeks, choice of self-treatment antibiotics regime based on :  Fluroquinolones  58%  83%  76%  67%  80%  50%  68%  Cotrimoxazole  2%  0%  0%  5%  0%  8%  3%  Rifaximin  2%  2%  10%  0%  6%  25%  5%  Metronidazole  20%  2%  10%  0%  1%  0%  6%  Azithromycin  57%  41%  19%  39%  32%  50%  38%  Not applicable  2%  2%  10%  5%  0%  8%  4%  Prefer not to say  2%  2%  5%  4%  0%  0%  1%  Other  0%  0%  10%  9%  4%  0% States for children less than 2 years of age 31 ; the child in our scenario was 4 years old.
Despite clinical benefits of prescribing antimicrobials and loperamide on symptoms, this now needs to be balanced against the increased evidence that the use of antibiotics for the treatment of TD increases that risk of colonization with multiresistant organisms, 12 thus potentially leading to inconsistency in advice given. More recently, it has been shown that the combination of loperamide and antibiotics may increase colonization risks even further, while use of loperamide alone did not seem to significantly increase that risk. 13 This recognition of the role antibiotics with or without loperamide may play in the risk of colonization with multi-resistant organisms is perhaps contributing to the heterogeneity in approach to moderate illness. 32 However, there was no significance difference (P ¼ 0.488) in the approach to prescribing antibiotics or not in those with moderate illness between respondents who identified as having changed practice as a result of recent literature which described this association and those who had not.
The potential for chronic gastrointestinal complaints such as irritable bowel syndrome following an episode of TD is also increasingly being recognized [33] [34] [35] although it is not yet clear whether early self-treatment with antibiotics can alter outcomes. 36 Our study has a number of limitations and is subject to selection bias given the voluntary participation. Of note is the relative under-representation of European travel health providers. A response rate was unable to be calculated given the open forums used to distribute the survey, meaning a denominator could not be readily obtained. It was clear from some free text responses that not all questions translated easily to all audiences, although some attempt was made to mitigate this when free text answers clearly indicated one of the pre-existing categorical options. Furthermore, the clinical scenarios provided on which conclusions regarding practitioner practice approaches have been based may not be generalizable to all pretravel patients seen. A major study limitation is that the survey asks practitioners how they would generally advise travellers, but in reality it is not possible to discuss each scenario with travellers. Thus, the survey attempts to capture the attitudes of practitioners in order to describe the diversity of counselling approaches, but if travellers are armed with antibiotics, loperamide and/or other medications to cover the range of illness severity that may occur, the differences in opinions and recommendations seen may not always translate into actual practice. Whether a traveller understands a practitioner's recommendations would be dependent on the provision of clear advice about how travellers should respond practically to a range of graspable scenarios, such as mild-to-moderate, tolerable diarrhoea versus severe, distressing or incapacitating symptoms and guidelines should reflect this.
Conclusion
There is practice diversity in the discussion of preventative techniques and prescribing of self-treatment medications for TD with additional variability occurring secondary to the respondents' professional background, region of practice and level of experience. For mild disease, most practitioners advocate a wait and see approach or the use of loperamide. In severe disease with fever, most would advocate seeking medical advice or a full course of antibiotics. A greater degree of heterogeneity exists in approaches around moderate disease with loperamide alone and antibiotics with or without loperamide all well represented practices. However, each of these different approaches are likely associated with differing degrees of risk of colonization with resistant organisms to the traveller. If clear evidence-based guidelines could address the competing issues of traveller health and morbidity with the risk of colonization with resistant organisms and provide consensus on appropriate indications for commencement of loperamide and/or antibiotics in moderate TD, this may lead to more consistent and appropriate prescribing practices.
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